Atherosclerosis
Volume 195, Issue 2 , Pages 287-296, December 2007

Involvement of transient receptor potential canonical 1 (TRPC1) in angiotensin II-induced vascular smooth muscle cell hypertrophy

  • Yoichiro Takahashi

      Affiliations

    • Second Department of Internal Medicine, Akita University School of Medicine, 1-1-1 Hondoh, Akita 010-8543, Japan
  • ,
  • Hiroyuki Watanabe

      Affiliations

    • Second Department of Internal Medicine, Akita University School of Medicine, 1-1-1 Hondoh, Akita 010-8543, Japan
  • ,
  • Manabu Murakami

      Affiliations

    • Department of Pharmacology, Akita University School of Medicine, Akita, Japan
  • ,
  • Takayoshi Ohba

      Affiliations

    • Second Department of Internal Medicine, Akita University School of Medicine, 1-1-1 Hondoh, Akita 010-8543, Japan
  • ,
  • Milena Radovanovic

      Affiliations

    • Second Department of Internal Medicine, Akita University School of Medicine, 1-1-1 Hondoh, Akita 010-8543, Japan
  • ,
  • Kyoichi Ono

      Affiliations

    • Department of Pharmacology, Akita University School of Medicine, Akita, Japan
  • ,
  • Toshihiko Iijima

      Affiliations

    • Department of Pharmacology, Akita University School of Medicine, Akita, Japan
  • ,
  • Hiroshi Ito

      Affiliations

    • Second Department of Internal Medicine, Akita University School of Medicine, 1-1-1 Hondoh, Akita 010-8543, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 18 884 6110.

Received 1 September 2006; received in revised form 20 December 2006; accepted 29 December 2006. published online 09 February 2007.

Abstract 

Angiotensin II (Ang II) induces vascular smooth muscle cell (VSMC) hypertrophy as one of the major events leading to atherosclerosis. Increased Ca2+ entry is an important stimulus for VSMC hypertrophy, but the association with Ang II remains to be determined. Transient receptor potential canonical 1 (TRPC1) forms store-operated Ca2+ (SOC) channels that are involved in Ca2+ homeostasis. Our aim was to ascertain the potential involvement of TRPC1 in Ang II-induced VSMC hypertrophy. For this purpose, we used cultured human coronary artery smooth muscle cells (hCASMCs). Store-operated Ca2+ entry (SOCE) increased in the Ang II-induced hypertrophied cells, and SOC channel blocker inhibited the Ang II-induced hypertrophic response. Although hCASMCs constitutively expressed TRPC1, C3, C4, C5, and C6, only TRPC1 increased in response to Ang II stimulation. TRPC1 siRNA decreased SOCE and prevented Ang II-induced hypertrophy. We found NF-κB binding sites in the 5′-regulatory region of the human TRPC1 gene. An electrophoretic mobility shift assay showed that Ang II increased the TRPC1 promoter's NF-κB binding activity. Co-treatment with NF-κB decoy oligonucleotides not only reduced TRPC1 expression, but also inhibited the hypertrophic responses. In conclusion, our data suggest that Ang II and subsequent NF-κB activation induces hCASMC hypertrophy through an enhancement of TRPC1 expression.

Keywords: Vascular hypertrophy, TRPC1, Calcium, NF-κB

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0021-9150(07)00037-8

doi:10.1016/j.atherosclerosis.2006.12.033

Atherosclerosis
Volume 195, Issue 2 , Pages 287-296, December 2007